Trial Profile

Phase 1 Clinical Trial of Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mitazalimab (Primary)
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions

Most Recent Events

25 Jan 2025 Trial design presented at the 2025 Gastrointestinal Cancers Symposium.
11 Jul 2024 According to Alligator Bioscience media release,on May 14 the company announced the initiation of the study, it is is being conducted by researchers at the Moores Cancer Center at UC San Diego, and financed by the US National Cancer Institute.
28 Jun 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com